Endocrine Abstracts

Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with aggressive behavior and poor prognosis, particularly when metastatic at diagnosis. To date, radical surgery, possibly associated to mitotane adjuvant therapy, is considered the best option for ACC treatment. However, the mean 5-year survival rate diminishes dramatically in metastatic ACC and chemo-resistance often develops. Thus, more specific and effective drugs for ACC treatment are urgently required. Th...

Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with a poor prognosis, particularly when metastatic at diagnosis. To date, radical surgery, possibly associated to mitotane adjuvant therapy, is the only available treatment. However, the mean 5-year survival rate drops under 10% in metastatic ACC and chemo-resistance often develops. Thus, more specific and effective drugs for ACC treatment are urgently required. The antidiabetic drug metformin, used in type 2 ...

Background: Immune checkpoint inhibitors (ICIs) are approved for the treatment of non-small cell lung cancer (NSCLC) and are associated with specific immune-related adverse events (iRAEs) including endocrine toxicities. However, data concerning the type, occurrence, and dynamics of iRAEs and their predictive value on treatment outcome are lacking. In this study, we evaluated the relation of iRAEs to anti-PD/L1 (programmed cell death protein/ligand-1) ICIs focusing particularly...

A functional sodium iodide symporter (NIS) is essential for radioiodine treatment of thyroid cancer. Unfortunately, most of de-differentiated tumours as well as anaplastic thyroid cancers loss the ability to concentrate iodine. Loss of NIS expression usually depends on epigenetic modifications, suggesting the use of epigenetic drugs as promising tools for re-differentiation. Panobinostat (LBH589) is a novel deacetylase inhibitor, acting at nanomolar concentrations, currently i...